Summary
BeiGene, Ltd. reported a significant increase in total revenues to $751.7 million for the first quarter of 2024, up 67.9% from the prior year, driven primarily by an 82.0% surge in product revenue to $746.9 million. This growth was predominantly fueled by strong performance in BRUKINSA, which saw a 131.1% year-over-year increase in net product revenue to $488.5 million, with notable expansion in the U.S. and Europe. The company continues to invest heavily in research and development, with R&D expenses increasing by 12.7% to $460.6 million, supporting its broad pipeline. Despite increased operating expenses, the company highlights improved operating leverage and progress towards sustainable profitability. However, BeiGene reported a net loss of $251.2 million for the quarter, although this represents an improvement compared to the $348.4 million net loss in the same period last year. Financially, BeiGene maintains a strong liquidity position with $2.8 billion in cash, cash equivalents, and restricted cash as of March 31, 2024. The company's total debt stands at $1.03 billion, with a significant portion maturing within the next 12 months. While the company is actively managing its growth and pipeline development, investors should monitor its continued progress in commercializing its approved medicines and advancing its pipeline candidates, alongside its efforts to manage increasing operational costs.
Financial Highlights
49 data points| Revenue | $751.65M |
| Gross Profit | $626.72M |
| R&D Expenses | $460.64M |
| SG&A Expenses | $427.43M |
| Operating Expenses | $888.07M |
| Operating Income | -$261.35M |
| Interest Expense | $12.40M |
| Net Income | -$251.15M |
| EPS (Basic) | $-0.19 |
| EPS (Diluted) | $-0.19 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.36B |
Key Highlights
- 1Total revenues increased by 67.9% to $751.7 million in Q1 2024 compared to Q1 2023.
- 2Product revenue surged by 82.0% to $746.9 million in Q1 2024, driven by strong sales of BRUKINSA.
- 3BRUKINSA net product revenue grew 131.1% to $488.5 million in Q1 2024, with significant growth in the U.S. and Europe.
- 4Research and development expenses increased by 12.7% to $460.6 million in Q1 2024.
- 5Selling, general, and administrative expenses increased by 30.1% to $427.4 million in Q1 2024, reflecting investment in commercial activities.
- 6Net loss for the quarter was $251.2 million, an improvement from $348.4 million in the prior year's quarter.
- 7Cash, cash equivalents, and restricted cash stood at $2.8 billion as of March 31, 2024, indicating a healthy liquidity position.